On Friday, JPMorgan issued a downgrade for bluebird bio (NASDAQ:BLUE) stock, shifting its rating from Neutral to Underweight. The downgrade follows bluebird bio's third-quarter financial results, which revealed a loss per share of $0.31. The company's revenue was reported at $10.6 million, falling short of the $18.3 million consensus estimate.
Additionally, bluebird bio announced a reduced cash runway, now expected to last into the first quarter of 2025, a revision from the previous forecast extending into the second quarter of 2025.
The biotechnology firm's financial challenges were further exacerbated by a recent proxy vote that failed to gather enough support to authorize a reverse stock split and an increase in the allocation for share issuance.
This outcome effectively limits the company's ability to raise capital through equity financing, given the current allocation of 35 million shares at the present share price, which would allow for approximately $13 million to be raised.
bluebird bio is also facing a tight deadline to secure at least $75 million in gross financing proceeds by December 20th to access the next tranche of funds, amounting to $25 million, as stipulated by the Hercules debt covenants. The company's path to bridging the cash gap is looking increasingly difficult without the option of equity financing.
Despite these financial headwinds, bluebird bio did achieve a significant milestone with the first infusion of Lyfgenia, marking the beginning of revenue recognition for the therapy. The company is also ramping up the rate of patient starts (cell collections) across its product portfolio.
However, it continues to operate with negative gross margins, which casts doubt on its ability to achieve positive operating cash flow in the second half of 2025.
Concerns have also been raised about the conversion rates from cell collection to infusion, with skepticism surrounding the company's target of reaching 40 infusions per quarter.
Given these challenges and the limited options available to the company to secure its financial future, JPMorgan has opted to downgrade bluebird bio's shares to Underweight.
In other recent news, Bluebird bio has reported significant developments in its business operations. During their Third Quarter 2024 Earnings Call, CEO Andrew Obenshain announced a rise in patient starts and a projected path to cash flow breakeven by the second half of 2025, contingent on securing additional cash resources.
Despite a dip in Q3 revenue to $10.6 million from $16.1 million in Q2, Bluebird bio anticipates a recovery to at least $25 million in Q4, as patient infusions are set to increase.
They are also implementing cost optimization strategies, including a planned 20% reduction in cash operating expenses by Q3 2025 and a reverse stock split proposal to regain NASDAQ compliance.
Additionally, the company has seen an increase in patient starts, from 27 in Q2 to 57 in Q3. Furthermore, more than half of U.S. states have confirmed coverage for Bluebird's LYFGENIA therapy.
These recent developments indicate the company's commitment to financial stability and growth, and their strategic efforts to overcome challenges.
However, it is important to note that these projections and strategies are subject to change and depend on various factors, including patient volumes and securing additional funding.
InvestingPro Insights
Recent InvestingPro data paints a challenging picture for bluebird bio, aligning with JPMorgan's downgrade. The company's market cap stands at a modest $70.31 million, reflecting investor concerns. bluebird bio's financial struggles are evident in its negative EBITDA of -$57.27 million and an alarming operating income margin of -638.21% for the last twelve months as of Q3 2024, underscoring the company's profitability issues mentioned in the article.
InvestingPro Tips highlight that bluebird bio is "quickly burning through cash" and "suffers from weak gross profit margins," corroborating the article's discussion on the company's financial challenges and negative gross margins. The stock's performance has been particularly poor, with a one-year price total return of -88.98% and a year-to-date return of -73.72%, reflecting the market's pessimism about the company's prospects.
These insights from InvestingPro provide additional context to the article's analysis of bluebird bio's financial difficulties and the rationale behind JPMorgan's downgrade. Investors seeking a more comprehensive understanding of bluebird bio's situation may find value in exploring the 13 additional InvestingPro Tips available for this stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.